
Adam Zaeske appointed as managing director of Takeda UK and Ireland
pharmafile | July 6, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Adam Zaeske, Takeda
Japanese pharma firm Takeda has appointed Adam Zaeske as managing director of Takeda UK and Ireland.
Zaeske has been with Takeda for 11 years and has held a number of positions, most recently as vice president of managed markets and trade for Takeda USA.
Commenting on his appointment, Zaeske says: “I am delighted to be joining the UK and Ireland team. The business is strong and is poised for several years of growth as we bring important new medicines forward to help patients that suffer from serious diseases.”
Zaeske received an MBA from Harvard Business School, and was previously a strategy consultant at Bain & Co and a finance manager at General Electric. At Takeda he led teams in marketing and sales, launching primary care and specialty products in gastroenterology, cardiovascular, metabolic, urology, and central nervous system therapeutic areas.
Zaeske will play a pivotal role at Takeda UK and Ireland, evolving with the changing healthcare environment by providing innovative specialist medicines in areas such as irritable bowel disease and oncology.
Related Content

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …






